Microcap Ledger Quoin Pharmaceuticals Ltd. $QNRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Ashburn, VA
- Shares outstanding
- 70,294,615 [10-Q 2026-08-14]
What the company doesAI summary of filing
Quoin Pharmaceuticals is a late-stage clinical specialty pharmaceutical company developing therapeutic products for rare and orphan diseases. The company's lead product, QRX003, is a topical lotion in pivotal clinical testing for Netherton Syndrome and also being studied for Peeling Skin Syndrome and other rare genetic skin diseases. QRX003 has received orphan drug designation, fast track designation, and rare pediatric disease designation from the FDA. The company is pre-revenue, having generated no product sales to date, and is pursuing a commercial strategy that includes establishing its own sales infrastructure in the U.S., Western Europe, and Japan, while partnering with distributors in other territories covering 61 countries. Quoin is also developing QRX008 for scleroderma and QRX009 (topical rapamycin formulations) for multiple rare conditions through research partnerships. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$10.37M | −$8.01M | $3.85M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$15.80M | −$13.54M | $3.82M | [DEF 14A 2026-07-16] |
| FY ended Dec 2024 | — | −$9.00M | −$7.86M | $3.62M | [DEF 14A 2026-07-16] |
- Quarterly cash burn
- −$4.01M
- Cash runway Estimate
- ~2.9 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2026-09-18; declared effective 2026-09-25 [S-3 2026-09-18]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-10-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-10-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-31] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-31 | Carter Denise P. | buy | 20,490 | $4.88 | [4 2026-09-01] |
| 2026-08-31 | Myers Michael | buy | 20,490 | $4.88 | [4 2026-09-01] |
| 2026-08-31 | Lawlor Sally Bridget | buy | 10,244 | $4.88 | [4 2026-09-01] |
| 2026-08-31 | Culverwell Anthony James | buy | 6,146 | $4.88 | [4 2026-09-01] |
| 2026-08-27 | Langer Dennis | grant | 34,534 | $5.15 | [4 2026-08-28] |
| 2026-08-27 | Culverwell Anthony James | grant | 31,352 | $5.15 | [4 2026-08-28] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-02 | DEF 14A | Proxy statement |
| 2026-09-25 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-22 | PRE 14A | Proxy statement |
| 2026-09-22 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-18 | S-3 | Registration statement |
| 2026-09-10 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-28 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-08-20 | 8-K | Director or officer change; Shareholder vote results; Other events |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-16 | DEF 14A | Proxy statement |
Alerts for $QNRX
Email me when Quoin Pharmaceuticals Ltd. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.